Homemed (PTY) Ltd v Claasen and Others (2022/004040)
Homemed (PTY) Ltd v Claasen and Others (2022/004040) [2022] ZAGPJHC 494 (1 August 2022)
The court found that the applicant established a prima facie right to restrain ELS from distributing DOA rapid screening tests without a medical establishment licence, as the products are, at least prima facie, medical devices not falling within the Class A exclusion of the 2017 Directive. The regulatory authority (SAHPRA), the FDA, and the EU MDCG support the classification of these products as Class B medical devices. The applicant demonstrated ongoing irreparable harm and lack of adequate alternative remedy, and the balance of convenience favoured granting interim relief. The court decline…
Source excerpt
- Restraint Of Trade
- Unlawful Competition
- Medical Device Regulation
- Interim Interdict
- Confidential Information